TY - JOUR
T1 - Crossover study with cisplatin or carboplatin in advanced ovarian cancer
AU - Repetto, L.
AU - Chiara, S.
AU - Mammoliti, S.
AU - Guido, T.
AU - Bruzzone, M.
AU - Secondo, V.
AU - Donadio, G.
AU - Odicino, F.
AU - Ragni, N.
AU - Conte, P. F.
AU - Rosso, R.
PY - 1990
Y1 - 1990
N2 - Fifty-seven patients who had progressed during or relapsed after randomized first-line combination chemotherapy containing cisplatin or carboplatin were entered into a crossover study in which the analog not previously assigned was administered alone as salvage treatment. Carboplatin and cisplatin were administered at doses of 400 and 100 mg/m2, respectively, every 28 days. Among the 24 patients enrolled in the cisplatin arm, 6 (25%) objective responses (ORs) (3 complete, 3 partial) were observed, whereas 3 partial responses were obtained in the 33 carboplatin-treated patient (9%). Analysis of results, according to response to first-line chemotherapy, demonstrated that the patients who progressed were sensitive only to cisplatin second-line treatment (OR: 3 12), with no responders among carboplatin-treated patients (OR: 0 11). All patients were treated on an outpatient basis and therapy-related toxic effects were mild, consisting chiefly of myelosuppression, and more frequent in the carboplatin group. In our opinion, carboplatin 400 mg/m2 per cycle is scarcely effective in patients with refractory or relapsed ovarian cancer pretreated with cisplatin regimens, whereas cisplatin 100 mg/m2 per cycle appears to be an effective salvage therapy even in patients not responding to carboplatin. The dose of carboplatin should be further escalated especially in refractory patients.
AB - Fifty-seven patients who had progressed during or relapsed after randomized first-line combination chemotherapy containing cisplatin or carboplatin were entered into a crossover study in which the analog not previously assigned was administered alone as salvage treatment. Carboplatin and cisplatin were administered at doses of 400 and 100 mg/m2, respectively, every 28 days. Among the 24 patients enrolled in the cisplatin arm, 6 (25%) objective responses (ORs) (3 complete, 3 partial) were observed, whereas 3 partial responses were obtained in the 33 carboplatin-treated patient (9%). Analysis of results, according to response to first-line chemotherapy, demonstrated that the patients who progressed were sensitive only to cisplatin second-line treatment (OR: 3 12), with no responders among carboplatin-treated patients (OR: 0 11). All patients were treated on an outpatient basis and therapy-related toxic effects were mild, consisting chiefly of myelosuppression, and more frequent in the carboplatin group. In our opinion, carboplatin 400 mg/m2 per cycle is scarcely effective in patients with refractory or relapsed ovarian cancer pretreated with cisplatin regimens, whereas cisplatin 100 mg/m2 per cycle appears to be an effective salvage therapy even in patients not responding to carboplatin. The dose of carboplatin should be further escalated especially in refractory patients.
UR - http://www.scopus.com/inward/record.url?scp=0025187933&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025187933&partnerID=8YFLogxK
U2 - 10.1016/0090-8258(90)90422-H
DO - 10.1016/0090-8258(90)90422-H
M3 - Article
C2 - 2227588
AN - SCOPUS:0025187933
VL - 39
SP - 146
EP - 149
JO - Gynecologic Oncology
JF - Gynecologic Oncology
SN - 0090-8258
IS - 2
ER -